



Preliminary Programme

Le Méridien Hotel, Nice, France

Excipients in Pharmaceutical Dosage Forms: The Challenge of the 21st Century

Thursday 14 May 1998

10.00–11.00 Registration

11.00 Opening of the conference
Chairman IPEC Europe

11.15 Keynote speech
Fernand Sauer, EMEA, UK (invited)

12.00 Lunch

IPEC Working group section:

13.10 International harmonisation of excipient standards
Dankward Jäkel, Novartis Pharma, Switzerland

13.40 GMP guidelines for excipients
Patricia Raffidison, Dow Corning, France

14.10 Safety aspects of excipients and toxicity testing
Dr Patricia Mailler, Servier, France

14.40 Development of Excipient Master Files
Dr B Carlin, FMC Europe, Belgium

15.10 Coffee break

15.40 Auditing Guidelines for GMP for (bulk) pharmaceutical excipients
Carl Mroz, Colorcon, UK

16.10 Panel discussion

Pharmaceutical excipient development:

16.30 Dilemma's in the development of novel excipients
Dr Chris Moreton, Mendell, USA

17.15–18.15 Cocktail reception

19.30 Dinner at a local restaurant

Friday 15 May 1998

Pharmaceutical information on the Internet

08.30 The Internet: a tool for delivering and exchanging information

Dr Anthony D'Emanuelle, School of Pharmacy and Pharmaceutics,
University of Manchester, UK

New excipient - novel pharmaceutical applications

09.10 Starch acetates: possibilities for use as excipients in controlled release tablet formulations

Professor Petteri Paronen, School of Pharmacy, University of Kuopio, Finland

09.50 Skin penetration enhancing aspects of excipients for topical use

Dr Johann Wiechers, Unichema International, The Netherlands

10.30 Coffee break

The BSE issue - status report and what to expect in future

11.00 Consequences of the BSE-crisis from an industry perspective

Professor Henk de Jong, Servier (to be confirmed)

11.40 Status of regulatory aspects concerning usage of bovine derived excipients

Speaker to be confirmed

12.30 Lunch

13.45 Workshops Delegates are asked to choose 2 of the following workshops

A. International harmonisation of excipient standards

Dr Dankward Jäkel, Novartis Pharma, Switzerland

B. GMP guidelines for excipients

Carl Mroz, Colorcon, UK

C. Safety aspects of excipients and the BSE-issue

Dr Patricia Mailler, Servier, France

D. Development of Excipient Master Files

Dr B Carlin, FMC Europe, Belgium

14.45 Coffee

15.15 Repeat of workshops

16.15 Conclusions of the workshops presented by the moderators

17.15 Close of conference

Enquiries: Anne Kember, Conference Administrator, Advanstar Communications,
Park West, Sealand Road, Chester CH1 4RN, UK
Tel: +44 (0)1244 378 888, Fax: +44 (0)1244 370 011, E-mail: akember@advanstar.com